drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (adoptive cell immunotherapy)
drug_description
Autologous, second-generation chimeric antigen receptor T cells engineered to recognize mesothelin on tumor cells and to secrete an IL-21–anti-PD-1 scFv fusion protein for localized cytokine support and checkpoint blockade, enhancing T-cell activation, proliferation, persistence, and cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous second-generation CAR T cells engineered to recognize mesothelin on tumor cells; CAR engagement (CD3ζ plus costimulatory signaling) activates T-cell cytotoxicity against mesothelin-positive cells, while secretion of an IL-21–anti-PD-1 scFv provides local IL-21 support and PD-1 checkpoint blockade to boost activation, proliferation, persistence, and resistance to exhaustion in the tumor microenvironment.
drug_name
Autologous mesothelin-targeted CAR-T cells (IL-21–anti-PD-1 scFv–secreting)
nct_id_drug_ref
NCT05779917